MIR184

Summary

MIR184 (microRNA 184, HGNC:31555) is a microRNA gene on chromosome 15q25.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of target mRNAs. This microRNA represents the most abundant miRNA in the corneal and lens epithelia of the eye and has been shown to interfere with target binding by another miRNA, miR-205. Through regulation of the VEGF and Akt signaling pathways, this microRNA may inhibit corneal angiogenesis. Mutations in the seed region of this microRNA cause familial keratoconus with cataract, also known as EDICT syndrome.

Source: NCBI Gene 406960 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31555
Approved symbol	MIR184
Name	microRNA 184
Location	15q25.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-184
Ensembl gene	ENSG00000207695
Ensembl biotype	miRNA
OMIM	613146
Entrez	406960
RNAcentral	URS000032015F — miRNA, 84 nt, 10 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384962

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384962 — 1 exons

Exon	Start	End
ENSE00001499969	79209788	79209871

Expression profiles

Bgee: expression breadth broad, 32 present calls, max score 76.04.

Top tissues by expression

32 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
islet of Langerhans	UBERON:0000006	76.04	gold quality
prefrontal cortex	UBERON:0000451	75.30	gold quality
monocyte	CL:0000576	71.18	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.10	gold quality
skin of leg	UBERON:0001511	66.94	gold quality
subcutaneous adipose tissue	UBERON:0002190	66.50	gold quality
esophagus mucosa	UBERON:0002469	66.31	gold quality
transverse colon	UBERON:0001157	66.07	gold quality
nucleus accumbens	UBERON:0001882	65.89	gold quality
body of stomach	UBERON:0001161	65.73	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	65.59	gold quality
frontal cortex	UBERON:0001870	64.99	gold quality
right hemisphere of cerebellum	UBERON:0014890	64.75	gold quality
anterior cingulate cortex	UBERON:0009835	64.69	gold quality
skin of abdomen	UBERON:0001416	64.64	gold quality
omental fat pad	UBERON:0010414	63.89	gold quality
right frontal lobe	UBERON:0002810	63.48	gold quality
Ammon’s horn	UBERON:0001954	63.32	gold quality
left ovary	UBERON:0002119	63.23	gold quality
hypothalamus	UBERON:0001898	63.20	gold quality
cerebellar hemisphere	UBERON:0002245	63.01	gold quality
Brodmann (1909) area 9	UBERON:0013540	61.95	gold quality
corpus callosum	UBERON:0002336	61.82	gold quality
tibial nerve	UBERON:0001323	60.95	gold quality
caudate nucleus	UBERON:0001873	60.79	gold quality
spleen	UBERON:0002106	59.20	gold quality
lung	UBERON:0002048	58.91	gold quality
putamen	UBERON:0001874	58.74	gold quality
substantia nigra	UBERON:0002038	57.60	gold quality
pituitary gland	UBERON:0000007	56.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.49

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• overexpression of miR-184 might play an oncogenic role in the antiapoptotic and proliferative processes of tongue squamous cell carcinoma; in addition, plasma miR-184 levels were associated with the presence of primary tumor (PMID:18451220)
• the corneal epithelial-specific miR-184 can interfere with the ability of miR-205 to suppress SHIP2 levels (PMID:19033458)
• Endogenous expression of miR-184 in cord blood is 58.4-fold higher compared with adult blood CD4+ T cells, and miR-184 blocks production of NFAT1 protein through its complementary target sequence on the NFATc2 mRNA without transcript degradation. (PMID:19286996)
• MYCN contributes to tumorigenesis, in part, by repressing miR-184, leading to increased levels of AKT2, a direct target of miR-184 (PMID:20409325)
• MIR-184 expression in renal carcinoma cells was significantly lower than that in adjacent tissue. (PMID:21844955)
• A mutation of the central base of the seed region of miR-184 was found to cause hereditary keratoconus and anterior polar cataract. miR-184 is highly expressed in corneal and lens epithelium. (PMID:21996275)
• Mutation altering the miR-184 seed region causes familial keratoconus with cataract (PMID:21996275)
• The single-base-pair substitution in the seed region of miR-184 is responsible for the disease phenotype observed in EDICT syndrome. (PMID:22131394)
• MiR-184 regulates the expression of AGO2. (PMID:23696368)
• The TNFAIP2 miRNA binding site rs8126 T>C single nucleotide polymorphism may be a marker for susceptibility to gastric cancer. (PMID:23724109)
• Two novel heterozygous substitution mutations in MIR184 were identified in the two patients with isolated keratoconus: miR-184(+8C>A) and miR-184(+3A>G). (PMID:23833072)
• We identified a heterozygous c.57 C > T mutation in miR-184 in the proband and two additional affected relatives on the maternal side. (PMID:24138095)
• PDCD4 as tumor suppressor regulated miR-184-mediated direct targeting of BCL2 and C-MYC. (PMID:24157866)
• Together, our result was shown that miR-184 might play a part in proliferation of HCC cells by INPPL1 loss and act as antiapoptotic factor in the development of HCC by inhibiting the activities of caspases 3/7. (PMID:24183204)
• miR-184 represents a potential onco-miR and plays an important role in HCC progression by suppressing SOX7 expression (PMID:24558429)
• Down-regulated miR184 expression was observed in non-small cell lung cancers. (PMID:24976536)
• Study is the first to show a novel regulatory role of SND1, a direct target of miR-184, in glioma progression, suggesting that the miR-184/SND1 axis may be a useful diagnostic and therapeutic tool for malignant glioma. (PMID:25216670)
• Downregulation of miR-184 was consistent with significantly lower levels of LAMP-1 (PMID:25251993)
• Downregulation of miR-184 inhibited cell viability. (PMID:25277131)
• MIR184 mutation arose independently in the Galician and Northern Irish families and thus represents a first observation of the recurrent germline mutation in the microRNA gene leading to the genetic disease (PMID:25373792)
• miR-184 could regulate TNFAIP2 expression and affected its translation in glioma. miR-184 could also inhibit glioma progression and might serve as a novel therapeutic target in glioma. (PMID:25888093)
• Decreased miR-184 is associated with invasiveness in Non-small Cell Lung Cancer. (PMID:25990966)
• The increased expression of miR-184 versus miR-205 in normal cornea samples implies a possible role of miR184 in cornea development and/or corneal diseases. (PMID:26380287)
• miR-184 showed an inhibitive activity of glioma U87MG cell line and breast cancer MCF-7 cell line in proliferation and invasion. miR-184 also could arrest cell cycle and adhesion by altering activity of signaling pathways. (PMID:26464691)
• miR-184 significantly attenuated the metastasis of small-cell lung cancer. (PMID:26587830)
• MiR-184 promotes tumor cell proliferation and invasion in osteosarcoma. (PMID:26600482)
• miR-184 together with pathologic diagnosis is critical for prognosis determination in epithelial ovarian cancer patients and help select treatment strategy (PMID:26601424)
• The up-regulation of miR-184 in pancreatic ductal adenocarcinoma (PDAC) may facilitate the proliferation and invasion ability, and inhibit apoptosis of tumor cells (PMID:26722418)
• Down-regulation of microRNA-184 may contribute to the development of cyanotic congenital heart disease via decreasing proliferation and inducing apoptosis of cardiomyocytes. (PMID:26823736)
• In follicular trachoma, expression of miR-155 and miR-184 is correlated with the severity of inflammation. (PMID:26842862)
• Regarding rs41280052, pre-mir-184, no significant association with keratoconus was observed. (PMID:26845316)
• Down-regulation of miR-184 is associated with up-regulation of VEGF and Wnt/beta-catenin expression as well as corneal neovascularization, indicating that miR-184 negatively regulates corneal neovascularization. (PMID:27018842)
• A decrease in miR-184 level by E6 oncoprotein may predict unfavorable response to cisplatin-based chemotherapy in HPV-infected non-small cell lung carcinoma patients via increasing Bcl-2 expression. (PMID:27083050)
• Data show that miR-184 was up-regulated in osteosarcoma patients treated with doxorubicin therapy and leads to poor response to drug therapy by targeting BCL2L1. (PMID:27222034)
• our findings suggest that miR-184 insufficiency is involved in the pathogenesis of dry age-related macular degeneration (PMID:27418134)
• Low miR184 expression is associated with clear-cell renal cell carcinoma. (PMID:27431728)
• Results suggest distinct roles of miR-184 during the growth, proliferation, and apoptosis of keratinocytes. (PMID:27571235)
• findings revealed the detailed role of the miR-184/iASPP axis in Central nervous system lymphoma (CNSL) and this axis might modulate the proliferation and invasion of CNSL via regulating the PI3K/Akt signaling pathway. (PMID:28012196)
• LncRNA UCA1 accelerated proliferation, increased cisplatin chemoresistance and restrained apoptosis partly through modulating SF1 via sponging miR-184 in oral squamous carcinoma cells. (PMID:29125238)
• these data demonstrate that glucose-mediated changes in AMPK activity are central for the regulation of miR-184 and other miRNAs in islets and provide a link between energy status and gene expression in beta cells. (PMID:29269398)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	dre-mir-184-1	ENSDARG00000081763
danio_rerio	dre-mir-184-2	ENSDARG00000083498
drosophila_melanogaster	mir-184	FBGN0262391

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.